Arvinas
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.About ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
CEOJohn G. Houston
CEOJohn G. Houston
Employees430
Employees430
HeadquartersNew Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded2013
Founded2013
Employees430
Employees430
ARVN Key Statistics
Market cap529.54M
Market cap529.54M
Price-Earnings ratio-1.49
Price-Earnings ratio-1.49
Dividend yield—
Dividend yield—
Average volume3.97M
Average volume3.97M
High today$8.00
High today$8.00
Low today$6.80
Low today$6.80
Open price$7.29
Open price$7.29
Volume8.60M
Volume8.60M
52 Week high$37.38
52 Week high$37.38
52 Week low$5.94
52 Week low$5.94
ARVN News
TipRanks 9h
Arvinas price target lowered to $10 from $20 at BMO CapitalBMO Capital analyst Evan Seigerman lowered the firm’s price target on Arvinas (ARVN) to $10 from $20 and keeps an Outperform rating on the shares. With the remo...
TipRanks 5d
Arvinas reports data from preclinical combination studies of ARV-393Arvinas (ARVN) presented data from preclinical combination studies of ARV-393, the company’s investigational PROteolysis TArgeting Chimera B-cell lymphoma 6 pro...
Analyst ratings
67%
of 21 ratingsBuy
66.7%
Hold
33.3%
Sell
0%
People also own
Based on the portfolios of people who own ARVN. This list is generated using Robinhood data, and it’s not a recommendation.